A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Clinical trial NCT04275518 · RECRUITING

Trial details

NCT number: NCT04275518
Sponsor: Ascentage Pharma Group Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)

Start date: 2020-07-06
Primary completion: 2025-12-31
Enrollment: 102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.